Nazia J. Khan

Nazia Khan is an associate in the Corporate Practice Group in the firm's Washington D.C. office and Co-Chair of the firm’s Canada Desk Team.

Areas of Practice

Ms. Khan’s practice focuses on corporate finance and securities laws. Ms. Khan represents underwriters and issuers in various industries including life sciences, healthcare, oil and gas, mining, technology, cannabis, food and beverage, transportation and REITs in capital markets transactions. Her experience includes leading both underwriters and issuers in public and private corporate finance transactions, including, but not limited to, initial public offerings, shelf registrations, registered direct transactions, private investments in public equity (PIPEs), private placements, secondary market purchases and other securities offerings. In addition, Ms. Khan’s experience includes initial public offerings of SPACs as well as de-SPAC transactions and public company mergers and acquisitions.

Ms. Khan also has experience with U.S. cross-border corporate law matters, including cross-border securities matters. She leads foreign issuers and investment banks in a broad range of public and private financings, including, but not limited to, financings under the U.S.-Canada Multijurisdictional Disclosure System (MJDS) and U.S.-foreign private placements including Rule 144A and Regulation S offerings.

Ms. Khan also counsels U.S. and foreign issuers in connection with corporate governance matters including reporting obligations under the Exchange Act, New York Stock Exchange (NYSE), the Nasdaq Stock Market (Nasdaq), Cboe and FINRA. Furthermore, she assists foreign issuers with securities quoted on the OTCQX and OTCQB with Principal American Liaison (PAL) related matters.

Nazia has been selected a New York Metro Rising Stars, Super Lawyers, from 2017 through 2023, Ones to Watch — Corporate Law, Best Lawyers, 2021 and 2022 and Who's Who in America, 2019.

Experience

Traditional IPOs:

• Represented Syra Health Corp. (Nasdaq: SYRA) in its initial public offering and listing on Nasdaq
• Represented Immix Biopharma, Inc. (Nasdaq: IMMX) in its initial public offering and listing on Nasdaq
• Represented Tharimmune, Inc. (Nasdaq: THAR) in its initial public offering and listing on Nasdaq
• Represented Greenwich LifeSciences, Inc. (Nasdaq: GLSI) in its initial public offering and listing on Nasdaq
• Represented Hoth Therapeutics, Inc. (Nasdaq: HOTH) in its initial public offering and listing on Nasdaq
• Represented Immuron Limited (Nasdaq: IMRN) in its initial public offering and listing on Nasdaq
• Represented Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) in its initial public offering and listing on Nasdaq
• Represented underwriters in an initial public offering and listing on Nasdaq of a company in the rideshare industry
• Represented underwriters in an initial public offering of and listing on Nasdaq of a biotechnology company focused on early cancer screening and detection

SPACs:

• Represented A.G.P./Alliance Global Partners in an initial public offering and listing on NYSE American of Ault Disruptive Technologies Corporation
• Represented A.G.P./Alliance Global Partners in an initial public offering and listing on Nasdaq of Digital Health Acquisition Corp.

Other Transactions:

• Represented LKQ Corp. (Nasdaq: LKQ) in a 144A offering of senior unsecured notes in the aggregate principal amount of $1.4 billion

• Represented Majesco in sale to private equity firm for $729 million

Honors

New York Metro Rising Stars, Super Lawyers, 2017-2023

Ones to Watch — Corporate Law, Best Lawyers, 2021, 2022

Who's Who in America, 2019

Articles

Corporate & Securities Law Blog Posts

• "Revised Schedule 13g Filing Deadlines Effective as of September 30, 2024 – What You Need to Know," October 1, 2024
• "SEC Adopts Amendments Regarding Insider Trading Plans and Related Disclosures," January 10, 2023

• "SEC Releases Pay Versus Performance Disclosure Requirements For Public Companies," September 19, 2022
• "SEC Proposes Amendments to Schedule 13 Beneficial Ownership Reporting Requirements," February 24, 2022

• "SEC Amends Definitions of “Accelerated Filer” and “Large Accelerated Filer” and Provides Relief to Small Issuers from Auditor Attestation Requirements," March 18, 2020

• "SEC Administrative Proceedings Against Public Companies for Failure to Remediate Material Weaknesses in Internal Control Over Financial Reporting," February 5, 2019 
• "Expansion of Regulation A to Reporting Companies: Increased Alternatives Now Available to Public Companies Seeking to Raise Capital or for Mergers and Acquisitions," February 1, 2019
• "The Effects of the SEC Shutdown on the Capital Markets," January 18, 2019
• "SEC Expands the Definition of 'Smaller Reporting Company,'" July 12, 2018

Cannabis Law Blog Posts

• "Reclassifying Cannabis as a Schedule III Substance – Will the DEA Agree?," August 31, 2023

• "FDA Commissioner Signals Enforcement Policy, Advancement of Research for CBD Products," March 9, 2020

Media Mentions

Speaking Engagements

• Panelist, “IPO, SPAC or Reverse Merger and At-The-Market, Registered Direct Offerings or a PIPE,” Planet Microcap Showcase, Las Vegas, NV, 2023
• Panelist, “Key Considerations for Deal Flow and Corporate Transactions in 2023,” South Asian Bar Association of North America, The Next Revolution, Boston, MA, 2023
• Speaker, "Benchmark Company," New York, New York
• Speaker, "H.C. Wainwright Conference," New York, New York
• Speaker, "National Investment Banking Association Conference," Fort Lauderdale, Florida
• Speaker, "ArcStone-Kingswood Growth Summit," Toronto, Canada
• Speaker, "50/50 Women on Boards," New York, New York
• Speaker, "Corporate Counsel Women of Color," Washington, D.C.
• Speaker, "South Asian Bar Association of North America," Boston, Massachusetts and Toronto, Canada
• Speaker, "National Asian Pacific American Bar Association," Seattle, Washington
• Speaker, "Ms. JD LaddHerUp," Sonoma, California

Events

Memberships

• Board Member, Ms. JD, Mentor
• Leadership Counsel on Legal Diversity